BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) Stock Price & Overview
FRA:BIO3 • DE0005227235
Current stock price
The current stock price of BIO3.DE is 30 EUR. Today BIO3.DE is down by 0%. In the past month the price increased by 15.38%. In the past year, price decreased by -23.66%.
BIO3.DE Key Statistics
- Market Cap
- 1.187B
- P/E
- N/A
- Fwd P/E
- 19.80
- EPS (TTM)
- -0.65
- Dividend Yield
- 0.09%
BIO3.DE Stock Performance
BIO3.DE Stock Chart
BIO3.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BIO3.DE. When comparing the yearly performance of all stocks, BIO3.DE is a bad performer in the overall market: 87.75% of all stocks are doing better.
BIO3.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BIO3.DE. Both the profitability and the financial health of BIO3.DE get a neutral evaluation. Nothing too spectacular is happening here.
BIO3.DE Earnings
BIO3.DE Forecast & Estimates
For the next year, analysts expect an EPS growth of 1600% and a revenue growth 11.95% for BIO3.DE
BIO3.DE Groups
Sector & Classification
BIO3.DE Financial Highlights
Over the last trailing twelve months BIO3.DE reported a non-GAAP Earnings per Share(EPS) of -0.65. The EPS decreased by -117.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.73% | ||
| ROE | -4.81% | ||
| Debt/Equity | 1.26 |
BIO3.DE Ownership
BIO3.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 31 | 44.64B | ||
| 1AE | ARGENX SE | 31.15 | 44.565B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.367B | ||
| ABVX | ABIVAX SA | N/A | 8.302B | ||
| 2X1 | ABIVAX SA | N/A | 8.246B | ||
| GLPG | GALAPAGOS NV | N/A | 1.628B | ||
| GXE | GALAPAGOS NV | N/A | 1.612B | ||
| NANO | NANOBIOTIX | N/A | 1.389B | ||
| PHARM | PHARMING GROUP NV | 49.21 | 1.054B | ||
| PHGN | PHARMING GROUP NV | 49.71 | 1.054B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.009B | ||
| IVA | INVENTIVA SA | N/A | 1.001B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 991.483M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About BIO3.DE
Company Profile
Biotest AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Dreieich, Hessen and currently employs 2,495 full-time employees. Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. The company develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
Company Info
IPO: 1987-10-14
BIOTEST AG-VORZUGSAKTIEN
Landsteinerstr. 5
Dreieich HESSEN DE
Employees: 2495
Phone: 4961038010
BIOTEST AG-VORZUGSAKTIEN / BIO3.DE FAQ
What does BIOTEST AG-VORZUGSAKTIEN do?
Biotest AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Dreieich, Hessen and currently employs 2,495 full-time employees. Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. The company develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
Can you provide the latest stock price for BIOTEST AG-VORZUGSAKTIEN?
The current stock price of BIO3.DE is 30 EUR.
What is the dividend status of BIOTEST AG-VORZUGSAKTIEN?
BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) has a dividend yield of 0.09%. The yearly dividend amount is currently 0.04.
What is the ChartMill rating of BIOTEST AG-VORZUGSAKTIEN stock?
BIO3.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is BIO3.DE stock listed?
BIO3.DE stock is listed on the Frankfurt Stock Exchange exchange.
What is the expected growth for BIO3 stock?
The Revenue of BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) is expected to grow by 11.95% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for BIO3 stock?
You can find the ownership structure of BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) on the Ownership tab.